926 related articles for article (PubMed ID: 16678639)
1. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
5. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
[TBL] [Abstract][Full Text] [Related]
6. [Non-hormonal treatments of postmenopausal osteoporosis].
Malaise O; Neuprez A; Reginster JY
Gynecol Obstet Fertil; 2008; 36(7-8):815-22. PubMed ID: 18653373
[TBL] [Abstract][Full Text] [Related]
7. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
9. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
10. Drug insight: Existing and emerging therapies for osteoporosis.
Mulder JE; Kolatkar NS; LeBoff MS
Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):670-80. PubMed ID: 17143314
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic concepts in the treatment of postmenopausal osteoporosis].
Leidig-Bruckner G; Ziegler R
Ther Umsch; 1994 Nov; 51(11):737-47. PubMed ID: 7839332
[TBL] [Abstract][Full Text] [Related]
12. Prevention of osteoporotic fractures in post-menopausal women.
Compston J
Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Jun; 14(2):251-64. PubMed ID: 11035905
[TBL] [Abstract][Full Text] [Related]
13. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
14. Management of osteoporosis due to ovarian failure.
Eastell R
Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
[TBL] [Abstract][Full Text] [Related]
15. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
16. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
17. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
18. Preventing osteoporosis in symptomatic postmenopausal women.
Gallagher JC; Levine JP
Menopause; 2011 Jan; 18(1):109-18. PubMed ID: 20661164
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
Miller RG
Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
[TBL] [Abstract][Full Text] [Related]
20. 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.
Seeman E; Eisman JA
Med J Aust; 2004 Mar; 180(6):298-303. PubMed ID: 15012571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
